|Bid||1.01 x 2200|
|Ask||1.02 x 1800|
|Day's Range||0.9800 - 1.0300|
|52 Week Range||0.7700 - 1.7800|
|Beta (3Y Monthly)||3.99|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 14, 2017 - Aug 18, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.76|
NEW YORK, Dec. 07, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Interpace Diagnostics Group (IDXG) is pleased to announce the launch of its newly designed company website including new product specific sites that allow for increased interactive functionality, enriched content and ease of navigation. In addition, these sites have been modernized to reflect the Company’s enhanced branding and appeal. Earlier this year, the Company updated the site’s ‘Investor Relations’ page to provide investors with easily accessible resources regarding Company news, events, presentations, and key financial information.
Interpace Diagnostics Group Inc (NASDAQ:IDXG), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is Read More...
Interpace Diagnostics Group, Inc. (IDXG) announced today a new scientific paper was published and the primary conclusion showed that DNA analysis using PancraGEN® has a favorable impact on patient outcomes particularly in patients with cysts that have worrisome features supporting more accurate surgery and surveillance decisions. The paper entitled “The Incremental Value of DNA Analysis in Pancreatic Cysts Stratified by Clinical Risk Factors” was published in the November edition of Gastrointestinal Endoscopy, the official peer-reviewed publication of the American Society for Gastrointestinal Endoscopy. The three DNA abnormalities examined in the study, all of which are included in the PancraGEN® assay, included: elevated DNA quantity, KRAS mutation, and loss of heterozygosity (LOH) mutations among a panel of key tumor suppressor genes.
Conference Call Tuesday, November 13, 2018 at 4:30 pm ET PARSIPPANY, NJ,, Nov. 13, 2018 -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG), a fully integrated commercial.
Interpace Diagnostics Group, Inc. (IDXG) announced today that the Company has been invited to participate at the 9th Annual Craig-Hallum Alpha Select Conference to be held on November 15, 2018 at the Sheraton New York Times Square Hotel. Companies, such as Interpace, have been individually selected by the Craig-Hallum research team based on several factors including above average growth prospects, attractive business models, competitive advantage, unappreciated value and strong management teams. The Alpha Select List companies will be presented to top institutional investors and analysts from across the country.
Interpace Diagnostics Group, Inc. (IDXG) announced today that it will report its third quarter 2018 financial results after the close of market on Tuesday, November 13, 2018 at 4:30 p.m. ET. Following the announcement, Interpace will host a conference call and webcast to discuss the Company’s financial results and provide a general business update.
Interpace Diagnostics (IDXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK, Oct. 30, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Interpace Diagnostics Group, Inc. (IDXG) announced that the Company presented new data at the 88th Annual Meeting of the American Thyroid Association (ATA) on Friday, October 5th supporting its molecular tests for thyroid cancer. The new interim data spanning over 300 samples from a two-year, “real world,” retrospective study highlighted the clinical utility of Interpace’s ThyGenX® thyroid oncogene panel in combination with its micro-RNA classifier, ThyraMIR®. J. Woody Sistrunk, MD, founder of the Jackson Endocrine and Thyroid Clinic in Jackson, MS, presented the results during a live poster session and as part of the Product Expo Theater presentation.
Interpace Diagnostics Group (IDXG) is pleased to provide a corporate update to shareholders on current business activities from its Chief Executive Officer, Jack Stover. “I would like to share my gratitude for each of you and my confidence and pride in the future of Interpace Diagnostics Group and provide you with a brief update on our current activities. As CEO, my conviction that we must succeed derives from the responsibility I personally embrace to lead our Company’s business strategy.
Interpace Diagnostics Group (IDXG) reported today that it has entered in to an Agreement with Piedmont Healthcare, Georgia’s largest healthcare system with nearly 600 locations, including 11 hospitals, that serves 2 million patients annually. Piedmont Atlanta Hospital, the system’s flagship hospital, is the largest tertiary care center in Georgia with more than 3,700 employees and 529 beds, specializes in cancer care and has been recognized in US News and World Report for its quality care delivery. The Agreement enables all physicians across the Piedmont Healthcare Network to use PancraGEN® for patients with indeterminate pancreatic cysts or other pancreaticobiliary lesions.
Interpace Diagnostics Group, Inc. (IDXG) announced today that it will be presenting new data from a multi-center Clinical Experience Study at the 88th Annual Meeting of the American Thyroid Association being held on October 5th in Washington, D.C. The data will be presented by J. Woody Sistrunk, MD, founder of the Jackson Endocrine and Thyroid Clinic in Jackson, MS, which was one of nine sites that participated in the study. According to the American Thyroid Association, approximately 15% to 30% of the 525,000 thyroid fine needle aspirations (FNAs) performed on an annual basis in the U.S. are indeterminate based on standard cytological evaluation, and thus are candidates for ThyGeNEXT testing.
NEW YORK, Sept. 25, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Interpace Diagnostics Group, Inc. (IDXG), announced today that it has received approval to launch its newest thyroid product, ThyGeNEXT™, in the States of Pennsylvania and New York. The Pennsylvania approval is final and the New York State approval is conditioned upon receipt of additional information requested. In the interim, Interpace is able to sell its unique ThyGeNEXT™/ThyraMIR® combination test to physicians in these States, which represent two of the largest state populations in the U.S. These approvals now enable physicians and patients in these markets where coverage has recently been granted by numerous payers to access ThyGeNEXT™.
The big shareholder groups in Interpace Diagnostics Group Inc (NASDAQ:IDXG) have power over the company. Institutions often own shares in more established companies, while it’s not unusual to see insidersRead More...
Interpace Diagnostics Group, Inc. (IDXG) (“Interpace” or “the Company”), a fully integrated commercial and bioinformatics company that provides beneficial molecular diagnostic tests and pathology services that improve patient diagnosis and management, announced today that the Company will participate in several local events in support of the following patient advocacy groups: Lustgarten Foundation Pancreatic Cancer Research (The Lustgarten Foundation), Thyroid, Head and Neck Cancer (THANC) Foundation, and Pancreatic Cancer Action Network (PanCAN). The Lustgarten Foundation and PanCAN are global organizations striving to advance scientific and medical research for pancreatic cancer in order to improve the lives of patients and their families.
Junior miners turned lower in sympathy with declining gold and silver contracts, while small biotech and medical diagnostic stocks picked up the slack, underpinned by sector funds probing new highs. September has a mixed reputation when it comes to small speculative plays, suggesting that traders focus their attention on penny stocks exhibiting the highest relative strength while avoiding falling knives that may face tax selling pressure in the fourth quarter. Low-priced energy stocks look like wild cards in this equation, with crude oil coming off lows while rising Middle East tensions add to sector buying power.